Retatrutide — The Triple Agonist That Is Rewriting the Rules of Weight Loss

28.7% average body weight reduction. In a Phase 3 clinical trial. Over 68 weeks.

To put that number in context — most bariatric surgery procedures produce average weight loss of between 25% and 30%. The most effective pharmaceutical compound previously available — tirzepatide — produces an average of around 20%. And retatrutide, in its first successful Phase 3 readout announced by Eli Lilly in December 2025, has already matched or exceeded surgical outcomes in a significant proportion of participants.

This is not hyperbole. Retatrutide shows among the highest weight loss results reported in any Phase 3 obesity drug trial to date — its triple agonist mechanism targeting GLP-1, GIP and glucagon simultaneously is genuinely novel in the field. FeelGoodPal

It is also still investigational. Retatrutide is not yet approved as a pharmaceutical medicine in any jurisdiction. Seven further Phase 3 trials are expected to complete in 2026, with regulatory approval anticipated in 2027 at the earliest. What exists right now is a compound available as a research grade peptide — with Phase 2 and Phase 3 data behind it that is extraordinary by any measure — and a research community paying very close attention.

This page covers what is currently known — the mechanism, the trial data, practical research protocol guidance and honest expectations about where this compound currently sits and where it appears to be heading.

What Makes Retatrutide Different

Both semaglutide and tirzepatide are covered in detail elsewhere in the library — and between them they represent the most effective weight loss compounds currently widely available. Retatrutide builds directly on the foundation they established and takes it a significant step further.

Semaglutide activates one receptor — GLP-1. Tirzepatide activates two — GLP-1 and GIP. Retatrutide activates three simultaneously — GLP-1, GIP and glucagon — making it a genuinely novel class of compound rather than simply a more potent version of what came before. Hippohive

That third receptor — glucagon — is where the additional power comes from. Glucagon is a hormone primarily associated with raising blood sugar, which might seem counterintuitive in a weight loss context. But glucagon receptor activation at the doses used in retatrutide research has a distinct and powerful effect on energy expenditure — essentially increasing the rate at which the body burns energy through a process called thermogenesis, rather than simply reducing how much energy goes in.

GLP-1 receptor agonism reduces appetite, improves glucose control and slows gastric emptying. GIP receptor agonism increases insulin sensitivity and contributes to body weight control. Glucagon receptor agonism promotes energy expenditure and hepatic lipid metabolism through thermogenesis — this arm of the mechanism also appears to drive PCSK9 degradation, which lowers LDL cholesterol in clinical readouts. Hippohive

The result is a compound that simultaneously reduces how much someone eats, improves how efficiently the body processes what it does eat, and increases the rate at which energy is expended — addressing three distinct aspects of the energy balance equation that no previous compound has targeted together in a single molecule.

The Clinical Evidence — What the Trials Show

Phase 2 — The New England Journal of Medicine (2023)

The Phase 2 trial published in the New England Journal of Medicine established retatrutide’s efficacy profile and safety data in a controlled setting — producing weight loss results that at the time were unprecedented for a Phase 2 trial and set expectations for what the larger Phase 3 programme might deliver.

TRIUMPH-4 — Phase 3 (December 2025)

In December 2025 Eli Lilly announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial evaluating the two highest investigational doses of retatrutide in adults with obesity or overweight and knee osteoarthritis. Clean Eatz

Participants taking retatrutide 12mg lost an average of 28.7% of their body weight at 68 weeks — among the highest average weight loss results ever reported in a Phase 3 obesity drug trial. Beyond weight loss, retatrutide reduced pain scores by up to an average of 75.8%, with more than one in eight retatrutide-treated patients completely free from knee pain at the end of the trial. Innerbody

TRIUMPH-1 — Phase 3 (May 2026)

In May 2026 — just weeks before this page was written — Eli Lilly announced positive topline results from TRIUMPH-1, a Phase 3 80-week trial in adults with obesity or overweight and at least one weight-related comorbidity without diabetes. At 80 weeks, all doses of retatrutide — 4mg, 9mg and 12mg — met the primary and key secondary endpoints for obesity, delivering clinically meaningful weight loss across every dose level studied. Wholistics Health

Seven additional Phase 3 trials are expected to complete in 2026. Analysts have noted that TRIUMPH-1’s 80-week length could deliver endpoints exceeding 30% weight loss — which would represent results beyond anything previously achieved in pharmaceutical weight management. Longevity.Technology

The direction of travel is unambiguous. Each successive trial has confirmed and extended what the earlier data suggested. Retatrutide is not an outlier — it is a compound whose results reflect a genuine and significant advance in the science of metabolic medicine.

Where Retatrutide Sits Right Now

Honesty about the current status of this compound is essential — and it is one of the things that distinguishes this site from sources that overstate what is currently available or accessible.

Retatrutide is investigational. It does not have regulatory approval in the UK, the US or anywhere else as of the time of writing. It is not an approved medicine in any jurisdiction as of April 2026. The pharmaceutical pathway to approval is progressing — with a 2027 approval anticipated based on the current trial programme — but that approval has not yet been granted. Hippohive

What exists in the meantime is a research grade compound available through the research peptide market — with the Phase 2 and Phase 3 data described above providing an evidence base that is genuinely compelling — and a research community following its development with significant interest.

As with every compound on this site, the [Safety & Legal UK] page covers the regulatory framework in full and should be read alongside this page.

Dosage and Protocol

The doses used in the TRIUMPH Phase 3 clinical trials — 4mg, 9mg and 12mg — represent the therapeutic doses that produced the extraordinary results described above. However the clinical trial escalation schedule does not reflect the most sensible starting point for those approaching retatrutide through a research protocol for the first time.

Retatrutide is a triple receptor agonist — it activates GLP-1, GIP and glucagon receptors simultaneously. That triple mechanism makes it significantly more potent than either semaglutide or tirzepatide, and experience within the research community consistently points to the same conclusion — starting considerably lower than the clinical trial initiation dose and building more gradually is both more comfortable and more sustainable for most people.

The Clinical Trial Doses — For Reference

The TRIUMPH programme evaluated retatrutide at three maintenance doses — 4mg, 9mg and 12mg — all administered once weekly subcutaneously. At 80 weeks in the TRIUMPH-1 trial, all doses met primary and key secondary endpoints for obesity, delivering clinically meaningful weight loss. The maximum dose of 12mg produced the 28.7% average weight loss figure that has attracted such significant attention. These are the doses the research is built on — and they represent the target range for a fully escalated research protocol. Wholistics Health

The Research Protocol — Start Low, Build Slowly

Based on real world experience with this compound, starting at just 0.5mg once weekly and increasing gradually every two weeks — but only when genuinely comfortable at the current dose — is the most sensible approach for anyone new to retatrutide.

The same principle that applies across every protocol on this site applies here with particular force — only move to the next dose when you feel genuinely ready to do so. With a triple agonist this is not simply good practice — it is the difference between a protocol you can sustain and one you abandon in the first month.

• Weeks 1 to 2: 0.5mg once weekly
• Weeks 3 to 4: 1.0mg once weekly
• Weeks 5 to 6: 2.0mg once weekly
• Weeks 7 to 8: 3.0mg once weekly
• Weeks 9 to 10: 4.0mg once weekly — first clinical trial dose level reached
• Weeks 11 to 12: 6.0mg once weekly
• Weeks 13 to 14: 8.0mg once weekly
• Weeks 15 to 16: 10.0mg once weekly
• Weeks 17 onwards: 12.0mg once weekly — assess response and maintain or adjust

For many people the meaningful therapeutic window begins well before 12mg — significant appetite suppression, metabolic improvement and weight loss are typically evident from the 4mg range onwards. There is no requirement to push to the maximum dose if excellent results and good tolerance are being experienced at a lower level. The right maintenance dose is the one that delivers results with genuine comfort — not necessarily the highest on the schedule.

Nausea, reduced appetite and digestive discomfort are the most commonly reported side effects in the early weeks — consistent with GLP-1 receptor activation and entirely manageable when the escalation is approached with patience and individual tolerance genuinely respected. If any dose increase produces significant discomfort, staying at the previous dose for an additional week or two before attempting the increase again is always the right call.

Administration

Once weekly subcutaneous injection into fatty tissue at the abdomen, upper thigh or upper arm. Rotate injection sites consistently to prevent localised tissue reactions. Timing relative to meals does not significantly affect efficacy given the compound’s extended half-life.

Supporting Supplements

The supplement considerations for retatrutide mirror those for semaglutide and tirzepatide — with one important additional emphasis. The magnitude of weight loss retatrutide is capable of producing makes nutritional support not simply advisable but critical.

Protein above all else. Potential weight loss of 25% or more of body weight carries the most significant risk of lean muscle mass loss of any compound in the library. Consistent adequate protein intake, protein-first meal planning and a high quality protein supplement to bridge any gaps are all strongly advisable throughout the protocol — not as an optional extra but as a fundamental part of getting the body composition outcome rather than simply a lower number on the scale.

Magnesium for energy metabolism, muscle function and sleep quality — all directly relevant during a protocol producing this level of physiological change.

Vitamin D — particularly important in the UK context where deficiency is widespread and its role in metabolic function and immune health is well established.

Zinc supports immune function, hormone regulation and cellular repair throughout a period of very significant physiological change.

Vitamin B12 given the substantial reduction in overall food intake — essential for energy metabolism and neurological function and worth specific attention when dietary intake is meaningfully reduced.

A comprehensive multivitamin as a non-negotiable daily safety net — ensuring the full micronutrient spectrum remains consistently available even when total caloric intake is substantially reduced over an extended period.

Foods That Complement Retatrutide

With appetite dramatically reduced — more so than with either semaglutide or tirzepatide in most users — the quality and composition of what is eaten becomes more important than at any other point in a weight loss protocol.

Every meal should be anchored by lean protein — chicken, fish, eggs, Greek yoghurt, cottage cheese — to protect lean tissue throughout what may be a period of very significant weight reduction. Oily fish two to three times per week delivers omega-3 fatty acids that support the anti-inflammatory metabolic environment and cardiovascular health — particularly relevant given retatrutide’s emerging profile on lipid markers including LDL cholesterol. High fibre vegetables at every meal support gut health and digestive comfort throughout the protocol. Avoiding ultra-processed and high glycaemic foods is especially important — the metabolic improvements retatrutide is driving across three receptor pathways are directly undermined by poor food quality choices.

Adequate hydration deserves specific mention — with overall food intake substantially reduced, water consumed through food decreases significantly. Deliberate and consistent hydration throughout the day supports the metabolic and cellular processes that underpin the weight loss this compound produces.

Lifestyle Considerations

Resistance training is more important here than with any other compound in this section. The magnitude of weight loss retatrutide can produce — potentially 25% or more of body weight — carries the most significant risk of lean tissue loss alongside fat of any compound in the library. Progressive resistance training throughout the entire protocol is not a recommendation — it is a necessity for anyone who wants to achieve genuine body composition improvement rather than simply a dramatically lower number on the scale.

Sleep quality shapes the hormonal environment in which retatrutide operates — protecting it is as relevant here as with every other compound, and the disruption that can accompany significant rapid weight loss makes deliberate sleep hygiene particularly important during a retatrutide protocol.

Stress management — chronic cortisol elevation works against fat loss and metabolic improvement regardless of what compounds are in use. The more powerful the compound, the more the foundations matter.

Alcohol is straightforwardly counterproductive during a retatrutide protocol — undermining caloric reduction, sleep quality, liver function and the metabolic improvements being driven across three receptor pathways simultaneously.

Peptide Pairing

Retatrutide’s triple mechanism makes additional weight loss compounds unnecessary and potentially inadvisable given the lack of studied interaction data for combined protocols.

CJC-1295 with Ipamorelin in a pre-sleep protocol is the most logical and well-reasoned pairing for anyone using retatrutide — supporting growth hormone release and lean tissue preservation during what may be a period of very significant caloric reduction. The timing separation between weekly retatrutide administration and daily pre-sleep GH peptide administration means there is no meaningful overlap or interaction concern.

BPC-157 is worth considering for those who experience significant gastrointestinal side effects in the early weeks of the escalation — its well documented protective effects on the gut lining and role in managing gut inflammation are directly relevant to the gastrointestinal profile of triple receptor agonism.

Realistic Expectations

Retatrutide is the most exciting compound in metabolic medicine right now. The trial data is extraordinary. The mechanism is genuinely novel. The direction of the research across eight ongoing Phase 3 trials is unambiguous.

It is also still investigational and the research grade compound available now — while backed by compelling Phase 2 and Phase 3 data — does not carry the regulatory validation that semaglutide and tirzepatide have achieved through their full approval processes. Understanding that distinction clearly before beginning is part of engaging with this compound responsibly.

For those who do — starting conservatively at 0.5mg, escalating patiently, respecting individual tolerance, and supporting the protocol properly with nutrition, resistance training and lifestyle — the realistic expectation based on the trial data is the most significant weight reduction available from any compound currently accessible in the research peptide market.

The foundations this site is built on matter more alongside retatrutide than alongside any other compound in the library. The compound is capable of producing extraordinary results. The results worth having are the ones built on a foundation strong enough to sustain them.

For research grade retatrutide with independent third party Certificate of Analysis documentation, Complete Peptides supplies verified compounds at [completepeptides.co.uk]

For context on how retatrutide compares with semaglutide and tirzepatide visit the [Weight Loss Overview]. For the complete fat loss approach combining retatrutide with supporting nutrition, timing and lifestyle see the [Fat Loss Protocol]. For the UK legal and regulatory framework visit [Safety & Legal UK].